ABSTRACT
4CPS-167 Figure 1 4CPS-167 Table 1Number of patients, administrations and days between each administration of ICIAtezolizumab Durvalumab Nivolumab Pembrolizumab Number of patients (%) 26 (10.24) 24 (9.45) 85 (33.46) 120 (47.24) Median number of administrations (IQR) 4 (3-8) 13 (5-24) 7 (3-22) 6 (3-13) Mean days between administrations (SD) 24 (7.43) 18 (7.67) 22 (31.38) 25 (15.99) We can see a significate decrease on the number of patients treated with an ICI between May 2020 and August 2020, possibly influenced by the decrease in the number of patients diagnosed with NSCLC during the COVID-19 pandemic.The mean days between each ICI administration was slightly above the approved posology, possibly due to delays because of adverse effects.References and/or AcknowledgementsConflict of InterestNo conflict of interest
ABSTRACT
Background and importance Patients with immune-mediated diseases (IMIDs) frequently need therapies from the hospital pharmacy. Due to the COVID-19 pandemic, a home delivery service (HDS) with telepharmacy follow-up was started to avoid unnecessary visits to hospital. Aim and objectives To describe the population that accepted the HDS and evaluate their satisfaction about it. Material and methods Descriptive retrospective observational study in a cohort of patients with IMIDs who had received HDS from February to August 2021. Data collected were age, sex, pathology, distance to hospital, number of shipments and satisfaction survey score. Surveys were made by telephone and scored the Pharmacy Service, the transport company and global satisfaction by means of seven questions (each with scores ranging from 1 to 5). Results 130 patients received HDS (7.23% of IMIDs outpatients), 116 of them were contacted for the survey. 81.9% were female. Median age was 74 (IQR 65.50-80.00) years. Pathologies distribution: 63 (54.31%) rheumatoid arthritis;18 (15.52%) spondyloarthropathies;14 (12.07%) multiple sclerosis;7 (6.03%) inflammatory bowel disease;5 (4.31%) psoriasis;5 (4.31%) connective tissue diseases and 4 (3.45%) other IMIDs (hydradenitis or vasculitis). 22.41% patients lived outside of the city centre where the hospital is located. Patients received an average of 2.17 (SD 1.12) shipments during these months. 84.48% patients were offered HDS from the hospital pharmacy;15.52% asked for the service themselves. Main reason chosen by patients to accepted HDS was the COVID-19 pandemic situation or self-insolation due to contact or infection (75.86%), followed by mobility difficulties (31.90%), distance to hospital (6.90%) and work schedule (0.86%). Average survey score for Pharmacy Service: 4.93 (SD 0.29) about pharmacist follow-up, 5.00 (SD 0) about correct medication and 4.98 (SD 0.13) about shipping material. In relation to the transport company, the scores were 5.00 (SD 0) about carrier treatment, 4.86 (SD 0.58) about schedule compliance and 5.00 (SD 0) about proper packaging conditions. Average score for global satisfaction was 4.99 (SD 0.10). Conclusion and relevance The pandemic situation increased HDS necessity (75.86% of patients requested it) but its continuity is justified specially due to mobility difficulties (31.90%) in older or incapacitated people, a frequent situation in IMIDs outpatients. Home delivery is a service that is highly valued by patients. Even so, telepharmacy follow-up and trying to adapt the shipping schedule could be areas to improve the service.